Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition by Ioannou, Nikolaos et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  48:  908-918,  2016908
Abstract. Drug-resistance is a major contributing factor for 
the poor prognosis in patients with pancreatic cancer. We have 
shown previously that the irreversible ErbB family blocker 
afatinib, is more effective than the reversible EGFR tyrosine 
kinase inhibitor erlotinib in inhibiting the growth of human 
pancreatic cancer cells. The aim of this study was to develop 
human pancreatic cancer cell (BxPc3) variants with acquired 
resistance to treatment with gemcitabine, afatinib, or erlotinib, 
and to investigate the molecular changes that accompany the 
acquisition of a drug-resistant phenotype. We also investigated 
the therapeutic potential of various agents in the treatment of 
such drug-resistant variants. Three variant forms of BxPc3 
cells with acquired resistance to gemcitabine (BxPc3GEM), 
afatinib (BxPc3AFR) or erlotinib (BxPc3OSIR) were devel-
oped following treatment with increasing doses of such drugs. 
The expression level, mutational and phosphorylation status of 
various growth factor receptors and downstream cell signaling 
molecules were determined by FACS, human phopsho-RTK 
array, and western blot analysis while the sulforhodamine B 
assay was used for determining the effect of various agents 
on the growth of such tumours. We found that all three BxPc3 
variants with acquired resistance to gemcitabine (BxPc3GEM), 
afatinib (BxPc3AFR) or erlotinib (BxPc3OSIR) also become 
less sensitive to treatment with the two other agents. Acquisition 
of resistance to these agents was accompanied by upregulation 
of p-c-MET, p-STAT3, CD44, increased autocrine produc-
tion of EGFR ligand amphiregulin and differential activation 
status of EGFR tyrosine residues as well as downregulation of 
total and p-SRC. Of all therapeutic interventions examined, 
including the addition of an anti-EGFR antibody ICR62, an 
anti-CD44 monoclonal antibody, and of STAT3 or c-MET 
inhibitors, only treatment with the STAT3 inhibitor Stattic 
produced a higher growth inhibitory effect in all three drug-
resistant variants. In addition, treatment with a combination 
of afatinib with either c-MET inhibitor Crizotinib or Stattic 
resulted in an additive or synergistic growth inhibition in all 
three variants. Our results suggest that activation of STAT3 
may play an important role in the acquisition of resistance 
to gemcitabine and HER inhibitors in pancreatic cancer and 
warrant further studies on the therapeutic potential of STAT3 
inhibitors in such a setting.
Introduction
Despite the advances in our understanding of cancer biology, 
diagnosis and therapy in the past decades, pancreatic cancer 
is still one of the deadliest types of human cancer, with a 
median survival rate of less than 6 months (1,2). Worldwide, 
there were an estimated 338,000 new cases of pancreatic 
cancer and 330,000 pancreatic cancer death in 2012 (3). It is 
the only type of cancer with an annual mortality rate which is 
so close to its annual incidence rate. This mainly stems from 
its late diagnosis, and its resistance to the current forms of 
therapy (4). Since its introduction in 1997, gemcitabine is the 
gold standard for the treatment of locally advanced and meta-
static pancreatic cancer (5,6). In addition, of the numerous 
agents investigated, only the addition of erlotinib (OSI-744), 
an epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, to gemcitabine therapy led to a modest, nonetheless 
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significant prolonged median overall survival in pancreatic 
cancer patients (7-9). The limited clinical benefit of erlotinib 
stems from the fact that the majority of pancreatic cancer 
patients simply do not respond to this treatment or acquire 
drug resistance following a short course of therapy (10). While 
the addition of two more effective chemotherapy combinations 
in the last decade, such as FOLFIRINOX (fluorouracil, irino-
tecan and oxaliplatin) and the combination of gemcitabine 
with Nab (nanoparticle albumin-bound)-paclitaxel improved 
the median survival rates for patients with metastatic disease, 
such combinational approaches are only suitable for patients 
with good performance status, with gemcitabine monotherapy 
remaining the only option for patients with poor performance 
status (6,11).
The extremely limited progress in improving survival 
outcomes in pancreatic cancer during the last decades, under-
lines the need not only for the development of more effective 
inhibitors for existing targets such as EGFR, but also it is 
imperative to develop new targeted agents and combination 
therapies for overcoming drug resistance.
We have shown previously that afatinib, an irreversible 
ErbB family blocker, is superior at inhibiting the growth of 
a panel of human pancreatic cancer cell lines compared to 
first generation reversible EGFR inhibitors such as erlotinib 
(OSI-774) or gefitinib (12,13). As drug-resistance is a major 
cause of treatment failure, development of drug-resistant 
pancreatic cancer models could help in unravelling the 
molecular mechanisms of acquired resistance and facilitate 
the discovery of novel and more effective approaches for the 
treatment of pancreatic cancer patients. We have shown previ-
ously that of seven pancreatic cancer cell lines investigated, 
BxPc3 cells exhibited the highest sensitivity to targeted agents 
afatinib and erlotinib (12). In this study, we developed three 
variants of the human pancreatic cancer cell line BxPc3, resis-
tant to afatinib, erlotinib and gemcitabine and investigated the 
possible molecular alterations accompanying the acquisition 
of a drug-resistant phenotype. In particular, we determined the 
expression levels of EGFR ligands, putative cancer stem cells 
(CSCs) and epithelial mesenchymal transition (EMT) markers, 
as well as the expression levels and activation status of several 
receptor tyrosine kinases (RTKs) including the HER family of 
receptors and several downstream cell signalling molecules in 
the parental pancreatic cancer and its drug-resistant variants. 
We also investigated the therapeutic potential of several agents 
in the treatment of such drug-resistant variants.
Materials and methods
Cell culture and tumour cell lines. BxPc3 pancreatic cancer 
cell line was purchased from the American Type Culture 
Collection (ATCC). BxPc3 cells were cultured routinely at 37˚C 
in a humidified atmosphere (5% CO2) in RPMI-1640 medium 
(Sigma-Aldrich, Dorset, UK) supplemented with 10% foetal 
bovine serum (PAA, UK), antibiotics penicillin (50 U/ml), 
streptomycin (0.05 mg/ml) and neomycin (0.1 mg/ml) and 
glutamine at a final concentration of 2 mM (Sigma-Aldrich), 
as previously described (14).
Antibodies and other reagents. Primary mouse antibodies 
HM50.67A and HM43.16B, were raised against the external 
domain of the HER-2 and EGFR, respectively (15). Mouse 
MAB3481 (anti-HER-3), MAB11311 (anti-HER-4), anti-insulin 
like growth factor receptor I (IGF-IR) mAbs and anti-E-
cadherin were purchased from R&D Systems (Abingdon, 
UK). Secondary FITC-conjugated rabbit anti-mouse mAb 
STAR9B was obtained from AbD Serotec (UK). Gemcitabine 
was acquired from Healthcare at Home (UK) while The irre-
versible pan-HER family blocker afatinib was developed by 
Boehringer Ingelheim (Austria) as previously described (16,17). 
OSI-774 was kindly provided by OSI-Phamarceutical (USA). 
Doxycycline, 5-fluorouracil (5-FU), oxaliplatin, and mouse 
anti-EGFR antibody were purchased from Sigma-Aldrich. 
Mouse antibodies against β-actin and vimentin as well as 
rabbit antibodies against AKT, Mitogen-activated protein 
kinase (MAPK), phospho-MAPK (Thr202/Tyr204), phospho 
AKT (S473), Signal transducer and activator of transcrip-
tion 3 (STAT3), p-STAT3 (Y705), Src, p-Src (Y416), c-MET 
(mouse), p-MET (Y1234/1235), p-EGFR (Y1086, 1068, 1143, 
1173, 1045), p-HER3 (Y1289), HER3, HER2 and p-HER2 
(Y1221/1222) were purchased from Cell Signalling, UK. The 
mouse anti-p-IGF-IR (Y1161) antibody and STAT3 inhibitor 
Stattic were purchased from Santa Cruz Biotechnology Inc. 
(Insight Biotechnology, UK).
Establishment of drug-resistant cell lines. We showed previ-
ously that of all pancreatic cancer cell lines investigated, BxPc3 
cells exhibited the highest overall sensitivity to treatment with 
either HER-targeted or chemotherapeutic agents (12). Drug-
resistant pancreatic cancer variants were developed by the 
treatment of BxPc3 cells with escalating doses of afatinib, 
erlotinib or gemcitabine. Cells were cultured routinely in small 
cell culture flasks (25 cm2) in growth medium/10% FBS in the 
presence of increasing doses of an inhibitor for a period of over 
6 months. Once tumour cells were able to maintain exponen-
tial growth at the presence of at least 3x the IC50 concentration 
of the drug, they were passed 15 times in drug-free medium 
and drug sensitivity was determined again to ensure that drug 
resistance acquisition was permanent.
Migration studies. For migration studies, 200 µl of cell suspen-
sion at a density of 2x105 cells/ml were mixed with 50 µl of 
serum free medium alone or with the inhibitors and then 
seeded into Transwell inserts (pore size 8 µm) of 24-well plates 
(Becton Dickinson Ltd., UK). The lower chamber was filled 
with 750 ml of growth medium supplemented with 10% FBS 
(as chemoattractant) and cells were incubated at 37˚C for 6 h. 
Following incubation, non-migrated cells were removed from 
the Transwell insert (upper surface of the membrane) using a 
cotton swab, and cells were fixed with ice-cold methanol for 
10 min at room temperature. Cells were stained with haema-
toxylin and were then washed. The number of cells that had 
migrated through the membrane was counted under a micro-
scope at x100 magnification. Five fields were counted in total 
for each sample. Results are expressed as the average number 
of migrated cells.
Flow cytometry. The cell surface expression of putative 
pancreatic CSCs (CD44, CD24 and CD133), HER family 
members (EGFR, HER-2, HER-3 and HER-4), IGF-IR 
and c-MET was assessed by flow cytometry as previously 
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described (12). A minimum of 10,000 events were recorded 
following excitation with an argon laser at 488 nm using the 
FL-1 detector (525 nm) of a BD FACsCalibur flow cytometer 
(Becton Dickinson Ltd.). Mean fluorescence intensity values 
were calculated using the Cellquest Pro software (Becton 
Dickinson Ltd.) and compared with those of negative controls 
(no primary antibody).
Growth inhibition studies. The effect of the various agents, on 
the growth of human cancer cell lines was investigated using 
the sulforhodamine B (SRB; Sigma-Aldrich) colorimetric assay 
as previously described (12). Interactions between the different 
agents when used in combination were assessed, using the 
combination index (CI) as described by Chou and Talalay (18). 
For each combination the two drugs were mixed at their 8X 
IC50 followed by 8 doubling dilutions. Interpretation of the 
results was based on the proposed descriptions for presenting 
the degrees of antagonism or synergism by Calcusyn software. 
In general, CI<0.9 indicates a synergistic effect while CI 
between 0.90-1.10 denotes an additive effect. CI>1.1 indicates 
antagonistic effects. Data analysis was performed using the 
Calcusyn software (Biosoft, Cambridge, UK).
Determination of autocrine ligand production by tumour 
cells. The level of autocrine EGFR ligands [EGF, TGF-α, beta-
cellulin, amphiregulin and heparin-binding EGF (HB-EGF)] 
secreted by the tumour cells into the culture supernatant was 
determined using the R&D Duoset ELISA kit following the 
manufacturer's instructions (R&D Systems). Briefly, tumour 
cells were grown in wells in a 6-well plate with 5 ml of growth 
medium supplemented with 10% FBS until almost confluent. 
Growth medium was replaced with fresh serum-free medium 
and incubated overnight at 37˚C. Supernatants were collected 
from each well and then the number of cells in each well was 
determined for all samples.
A standard curve was created for each ligand investigated, 
using a four parameter logistic (4-PL) curve-fit. Concentration 
of ligands in cell supernatants was determined from each 
standard curve using GraphPad prism 6 software (GraphPad 
Software, Inc., La Jolla, CA, USA).
Analysis of receptor tyrosine kinase (RTK) phosphorylation 
status by the Proteome Profiler 96 Human Phospho-RTK 
Array 1. The basal phosphorylation status of 16 RTKs (EGFR, 
HER-2, HER-3, HER-4, HGF-R (c-MET), IGF-IR, INS-R, 
M-CSF R, MSP-R, PDGFRa, PDGFRb, SCF R, Tie-2, vEGFR1, 
vEGFR2, vEGFR3) was investigated in BxPc3 parental cells 
and its drug-resistant variants using the Proteome Profiler 96 
Human Phospho-RTK Array 1 (Catalog # ARZ001) following 
the manufacturer's instructions (R&D Systems). The plate was 
imaged using a G-box imaging system (Invitrogen, UK) and 
data analysis was performed using q-view software (quansys 
Biosciences, Logan, UT, USA).
Western blotting. Parental cancer cells and drug-resistant vari-
ants were grown to near confluency in 6-well culture plates 
containing 5 ml of 10% FBS RPMI growth medium. Cells were 
washed once with 5 ml of RPMI/0.5% FBS, lysed using 400 µl 
of lithium dodecyl sulfate (LDS) lysis buffer (Invitrogen) 
containing protease inhibitor cocktail (Sigma-Aldrich). Cell 
lysates were heated at 90˚C for 5 min, protein samples (25 µg) 
were separated on 4% to 12% Bis-Tris gels (Invitrogen) and 
transferred to polyvinylidene difluoride (PVDF) membranes 
(Invitrogen). The PvDF membranes were probed with anti-
bodies against several cell signalling molecules at optimal 
concentrations according to the manufacturer's instructions. 
The specific signals were detected using the WesternBreeze 
chemiluminescence kit (Alkaline phosphatase conjugated 
secondary antibody) (Invitrogen). Results were visualized 
using the G-box imaging system (Syngene, Cambridge, UK).
Mutational analysis by next generation sequencing. 
Characterization of somatic mutations in the parental BxPc3 
cell line and its drug-resistant clones was performed by using 
the Ion AmpliSeq™ Cancer Hotspot Panel v2 (CHPv2) 
(Life Technologies, Paisley, UK) following the manufac-
turer's instructions. Ion AmpliSeq CHPv2 is a next generation 
sequencing assay which can identify numerous somatic muta-
tions [2855 hot spots/catalogue of somatic mutations in cancer 
(COSMIC) mutations] from 50 genes including EGFR, HER2, 
KRAS, p53, PIK3CA, PTEN and c-MET among others. For 
Table I. Changes in the sensitivity of drug resistant variants to various inhibitors. 
 IC50
 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cell line Gemcitabine 5-FU Doxycycline Oxaliplatin Afatinib Erlotinib Gefitinib NVP-AEW541 Crizotinib
BxPc3 parental 7.5 nM 655 nM 11 µM 3.8 µM 17 nM 1.45 µM 2.3 µM 1.25 µM 1.71 µM
BxPc3AFR 386 nM 555 nM 10.68 µM 3.2 µM 1.32 µM 4.3 µM 8.3 µM 1.63 µM 1.46 µM
  Fold change 51.46a 0.84 0.97 0.84a 77.64a 2.96a 3.55a 1.30 0.85
BxPc3GEMR 663 nM 613.5 nM 7.2 µM 1.34 µM 1.2 µM 6.1 µM 5.545 µM 1.34 µM 1.24 µM
  Fold change 88.4a 0.93 0.75 0.35a 70.88a 4.20a 2.37a 1.07 0.72
BxPc3OSIR 507.5 nM 1.2 µM 7.3 µM 11.25 µM 3.1 µM 5.25 µM 6.4 µM 3.25 µM 1.61 µM
  Fold change 67.66a 1.83a 0.66 2.96a 182.3a 3.62a 2.74a 2.58a 0.93
Drug sensitivity was determined by the SRB colorimetric assay and IC50 values were calculated as described in Materials and methods. (ap<0.05 
compared to parental cell line).
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a detailed list of all genes and hotspots included in the assay 
please see Table I). Genomic DNA was extracted from each 
cancer cell line using the AllPrep DNA/RNA/Protein Mini 
kit (qiagen, UK) according to the manufacturer's instruc-
tions. Analysis of sequencing data was performed using the 
Ion Reporter software (Life Technologies) and confirmed by 
using NextGENe® software (Softgenetics, UK).
Statistical analysis. The unpaired two-tailed Student's t-test 
was used for comparing mean values between two groups. 
Data are presented as mean ± SD. p<0.05 was considered 
statistically significant.
Results
Establishment of drug-resistant pancreatic cancer cell lines. 
In this study, we established three variant forms of BxPc3 
cells; with acquired resistance to gemcitabine (BxPc3GEMR), 
afatinib (BxPc3AFR) and erlotinib (BxPc3OSIR). IC50 values 
for each drug in the parental cells and their drug-resistant 
variants, following at least 15 passages in drug-free medium, 
are presented in Table I. The morphology of the drug-
resistant variants is presented in Fig. 1A. All BxPc3 derived 
drug-resistant cell lines, gained increased migration ability 
compared to the parental cell line indicating a higher meta-
static potential (Fig. 1B). However, there were no changes in 
the expression of EMT markers (vimentin and E-cadherin) 
in the drug-resistant variants compared to the parental cell 
line (Fig. 1C).
Growth response of parental and drug-resistant pancre-
atic cancer cell variants to treatment with various agents 
following acquisition of drug resistance. All three drug-resis-
tant variants exhibited significant changes in their sensitivity 
to treatment with several agents compared to their parental 
counterpart (Table I). For example, BxPc3AFR variant with 
acquired resistance to afatinib (77.64-fold change, p<0.05), 
also developed resistance to erlotinib (2.96-fold change, 
p<0.05), gefitinib (3.55-fold change, p<0.05) and gemcitabine 
(51.46-fold change, p<0.05) (Table I). Similarly, BxPc3GEMR 
and BxPc3OSIR variants demonstrated a reduced sensitivity 
to treatment with gemcitabine, afatinib, erlotinib and gefitinib. 
For example, BxPc3OSIR variant in addition to erlotinib, 
became highly resistant to treatment with afatinib with 
182-fold increase in its IC50 value (p<0.05) (Table I). However, 
the changes in sensitivity to other agents differed consider-
ably in each of these cell lines. For example, in comparison to 
the parental BxPc3 cells, both BxPc3AFR and BxPc3GEMR 
cell lines became more sensitive to treatment with oxaliplatin, 
while BxPc3OSIR cells became less sensitive (Table I).
Acquisition of resistance to treatment with afatinib and 
gemcitabine is accompanied by upregulation of EGFR 
ligand amphiregulin (AR) in pancreatic cancer variants. 
Of all growth factors investigated, BxPc3 parental cell line 
was found to secrete only AR. Of note, acquired resistance 
to afatinib and gemcitabine in pancreatic cancer cells 
was accompanied by a 3-fold increase in secretion of AR. 
The concentration of AR secreted by BxPc3, BxPc3AFR, 
BxPc3GEMR and BxPc3OSIR was 120, 338.5, 367.8 and 
142.9 pg/ml, respectively (Fig. 2A). Treatment of parental 
BxPc3 cells with 20 nM of AR for 15 min was accompanied 
by increased phosphorylation of all EGFR tyrosine residues 
and MAPK but it had no effect on the phosphorylation status 
of STAT3 and AKT (Fig. 2B).
Expression levels of putative pancreatic CSC markers, HER 
family members, IGF-IR and c-MET in drug resistance variants. 
Figure 1. Morphology (A), migration ability (B), and expression of EMT markers vimentin and E-cadherin (C) in the drug-resistant pancreatic cancer cell lines 
and their parental counterpart (original magnification, x20). Results are expressed as the average number of migrated cells of five fields in two independent 
experiments (*p<0.05) [Error bars, standard deviation (SD)]. Expression of EMT markers was investigated by western blot analysis as described in Materials 
and methods.
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The cell surface expression of putative pancreatic cancer 
CSC markers CD44, CD24 and CD133, as well as all members 
of the HER family, IGF-IR and c-MET was analysed in the 
parental BxPc3 cell line and its drug-resistant variants by flow 
cytometry. Both BxPc3AFR and BxPc3OSIR variants exhib-
ited a statistically significant increase in CD44 expression with 
a 3.14- and 2.23-fold change (p<0.05), respectively, compared 
to the parental BxPc3 cells. No differences were observed in 
the expression of CD24 while all cell lines were found to be 
negative for CD133 (Table II). There was a small decrease in 
the expression of several markers in BxPc3GEMR, however, 
none of these was found to be statistically significant (Table II).
Upregulation of phosphorylated c-MET and STAT3 in 
drug-resistant variants. Next, we investigated the basal phos-
phorylation status of 16 RTKs in BxPc3 parental cells and 
its drug-resistant variants. Our aim was to determine whether 
acquisition of resistance was accompanied by any changes 
in the phosphorylation status of major RTKs. Noteworthy, 
detectable levels of phosphorylated c-MET receptor were 
observed only in BxPc3AFR and BxPc3GEMR variants 
(Fig. 3). The upregulation of p-c-MET in the BxPc3AFR and 
BxPc3GEMR-resistant variants was confirmed by subsequent 
western blot analysis, which also showed upregulation of 
p-c-MET in the BxPc3OSIR variant which was not detectable 
by the RTK assay (Fig. 4).
A detailed analysis of the phosphorylation status of several 
tyrosine residues of the EGFR, revealed several differences 
between the drug-resistant variants and the parental cell 
line (Fig. 4). While there were no major differences in the 
phosphorylation status of EGFR tyrosine residues Y1148 and 
Y1045 between the parental cell line and the drug-resistant 
variants, a significant increase in phosphorylation levels of 
Y1068 in all three BxPC3 variants. In addition, the phosphory-
lation of EGFR residues Y1173 and Y1086 was increased in 
some drug-resistant variants (Fig. 4). Next, we examined the 
activation status of several downstream signalling molecules 
including SRC, MAPK, AKT and STAT3 in the parental cell 
line and its drug-resistant variants showing downregulation of 
pAKT in BxPc3AFR and BxPc3OSIR but not BxPc3GEMR 
cells. In addition, there was an upregulation of pSTAT3 in 
all drug-resistant variants compared to the parental cell line. 
Interestingly, total and phosphorylated SRC was downregu-
lated in all resistant clones (Fig. 4).
Figure 2. Amphiregulin concentration levels in culture medium as determined by ELISA (A) and effect of amphiregulin treatment on activation status of 
EGFR tyrosine residues, AKT, MAPK and STAT3 on BxPc3 parental cells (B). Amphiregulin was the only ligand found positive in the samples investigated 
(mean of two individual experiments, n=6) (error bars=SD) (A). BxPc3 cells were treated with amphiregulin (20 nM) for 15 min then lysed, proteins were 
separated by SDS-PAGE, transferred to PvDF membranes and probed with the antibodies of interest. Representative of two independent experiments (B).
Table II. Changes in the expression of CSC markers (CD44, CD24 and CD133), HER family members, IGF-IR and c-MET in 
drug resistant established cell lines relative to their parental counterparts. 
Cell line EGFR HER-2 HER-3 HER-4 IGF-IR c-MET CD44 CD24 CD133
BxPc3AFR 0.97 0.59 1.07 N/A 1.04 0.96 3.14a 0.69 N/A
BxPc3GEMR 0.69 0.66a 0.70 N/A 0.76 0.84 0.86 0.60 N/A
BxPc3OSIR 1.17 0.78 1.34 N/A 1.07 0.80 2.23a 0.83 N/A
Cell surface expression of all markers was determined by flow cytometry as described in Materials and methods. Changes in expression are 
presented as expression in drug resistant cells relative to their parental cell lines (fold change) (ap<0.05). Two independent experiments were 
performed for each cell line including parental cells. N/A, not applicable.
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Effect of afatinib and crizotinib treatment on the phosphory-
lation status of EGFR, HER3, p-c-MET and downstream 
molecules STAT3, AKT and MAPK. Since upregulation of 
phorphorylated c-MET and STAT3 was found in all drug-resis-
tant variants, we examined the effect of crizotinib, a c-MET 
inhibitor, when used alone or in combination with afatinib on 
the activation of downstream molecules STAT3, AKT and 
MAPK. At 400 nM, crizotinib blocked completely the activa-
tion of c-MET but had no effect on the activation status of 
either STAT3 or HER family members, EGFR (Y1068) and 
HER3 (Fig. 5). Similarly, treatment with afatinib had no effect 
on the phosphorylation levels of STAT3, or c-MET, however, it 
Figure 3. Basal phosphorylation status of 16 receptor tyrosine kinases (RTKs) in BxPc3 cells and its drug-resistant clones. Phosphorylation levels of all RTKs 
investigated are expressed relative to the levels of the parental BxPc3 cell line (control=1) (three independent experiments) (error bars=SD).
Table III. Mutations of BxPc3 cell line as determined using next generation sequencing (cancer hotspot v2 amplicons).
Locus Genotype Control genotype Type Gene Location AA change
chr4:1807894 A/A G SNv FGFR3 Exonic Synonymous
chr4:55141050 AGCCCGGATGGACATG/ AGCCCAGATGGACATG SNv PDGFRA Exonic Synonymous
 AGCCCGGATGGACATG
chr4:55152040 C/T C SNv PDGFRA Exonic Synonymous
chr4:55593481 A/G A SNv KIT Exonic Synonymous
chr4:55972974 A/A T SNv KDR Exonic p.Gln472His
chr4:55980239 T/T C SNv KDR Intronic N/A
chr5:112175769 CAG/CAG CGG SNv APC exonic Synonymous
chr7:55249063 G/A G SNv EGFR Exonic Synonymous
chr11:534242 A/G A SNv HRAS Exonic Synonymous
chr13:28610183 G/G A SNv FLT3 Intronic N/A
chr17:7578190 C/C T SNv TP53 Exonic p.Tyr181Cys
chr17:7579470 CGC/CGC CGG SNv TP53 Exonic p.Pro33Arg
chr22:24176287 A/A G SNv SMARCB1  Intronic  N/A
No additional genetic variations were detected in the drug resistant cell lines when compared with the parental cell line. Control genotype refers 
to the reference genome. AA, amino acid; N/A, not available; SNv, single nucleotide polymorphism.
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was more effective at blocking the phosphorylation of EGFR 
at tyrosine 1068 in the parental cell line compared to the 
drug-resistant variants suggesting that STAT3 activation was 
a result of a c-MET and HER family members-independent 
mechanism (Fig. 5).
Next generation sequencing using the CHPv2 revealed no 
differences between the parental cell line and drug-resistant 
clones. Next generation sequencing data analysis revealed 
13 SNvs in the parental and the drug-resistant variants, 3 of 
which were found to be intronic. Of the 10 exonic SNvs only 
3 led to amino acid substitutions, 2 of which in the TP53 gene 
and one in the KDR gene (Table III).
Drug-resistant variants exhibited increased sensitivity to 
treatment with Stat-3 inhibitor Stattic. As there were higher 
Figure 4. Basal levels of phosphorylated HER family members, c-MET and downstream molecules SRC, AKT, MAPK and STAT3 in parental BxPc3 cells 
and drug-resistant cell lines BxPc3AFR, BxPc3GEMR and BxPc3OSIR. Cells were grown to near confluence in 10% FBS at 37˚C, then lysed, proteins were 
separated by SDS-PAGE, transferred to PvDF membranes and probed with the antibodies of interest. Representative of two independent experiments.
Figure 5. Basal levels of phosphorylated HER3, EGFR (Y1068) c-MET and downstream molecules AKT, MAPK and STAT3 in parental BxPc3 cells and 
drug-resistant cell lines BxPc3AFR, BxPc3GEMR and BxPc3OSIR either grown in 10% FBS supplemented growth medium alone or with Afatinib, Crizotinib 
or their combination. Cells were grown to near confluence in 10% FBS at 37˚C, and incubated overnight. Cells were then lysed, proteins were separated by 
SDS-PAGE, transferred to PvDF membranes and probed with the antibodies of interest. Representative of two independent experiments.
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levels of phosphorylation of STAT3 in all drug-resistant vari-
ants, we sought to investigate the inhibitory effect of STAT3 
inhibitor Stattic, when used alone or in combination with 
afatinib or gemcitabine. All drug-resistant variants exhibited 
higher sensitivity to STAT3 inhibition with IC50 values of 
750 nM (p=0.012), 760 nM (p=0.012) and 1.26 µM (not signifi-
cant, p=0.22) in BxPc3AFR, BxPc3GEMR and BxPc3OSIR, 
respectively, compared to the IC50 value of 1.51 µM in the 
parental cell line. Of note, treatment of the parental BxPc3 
cell line with a combination of afatinib with STAT3 led to 
synergism with a CI value range of 0.5-0.6 while the same 
combination had an additive effect in the drug-resistant vari-
ants (Table Iv). Similarly, the combination of Crizotinib with 
afatinib led to a strong synergistic effect in the parental cell 
line, it had an additive or slight synergistic effect in all drug-
resistant variants (Table Iv).
Discussion
Drug resistance is one of the greatest challenges in clinical 
oncology (6). Molecular changes that lead to a decreased 
influx of the drug [low expression of the human equilibrative 
nucleoside transporter-1(hENT1)] or a low rate conversion of 
gemcitabine to its active metabolites, caused by a low efficacy 
of deoxycytidine kinase (dCK) are some of the mechanisms 
which have been identified so far for acquired resistance to 
gemcitabine (19,20). Similarly, a number of mechanisms have 
been identified for acquired resistance to HER inhibitors, 
including the HER family member modification (e.g. EGFR 
T790M mutation), the activation of alternative signalling path-
ways (e.g. c-MET, IGF-IR), production of autocrine ligands 
or mutations in downstream signalling molecules such as 
K-RAS (10,21,22).
In our previous study, we investigated and reported the 
growth response of a panel of seven human pancreatic tumour 
cells lines (BxPC-3, AsPC-1, FA6, PANC-1, CAPAN-1, 
MiaPaca2, PT-45) to the treatment with a wide range of 
agents including afatinib, and erlotinib. We have shown that 
of these agents, afatinib was more effective than erlotinib 
in inhibiting the growth of these cancer cell lines in vitro. 
More importantly, of all the cell lines examined in that study, 
BxPC3 cells were the most sensitive to treatment with both 
afatinib and erlotinib, with IC50 values of 11 and 1,200 nM, 
respectively (12). Since KRAS mutations have already been 
established as a mechanism of resistance to EGFR inhibitors, 
and in BxPC-3 cells it is the only one with a wild-type KRAS 
gene and consequently most sensitive to treatment with both 
afatinib and erlotinib, we developed variants of BxPC-3 cells 
with acquired resistance to these drugs.
In this study, we sought to investigate molecular 
changes accompanying the acquisition of drug resistance to 
HER-targeted therapy or gemcitabine in pancreatic cancer, 
and to determine therapeutic interventions that could over-
come this phenomenon. We found that acquired resistance to 
one agent such as gemcitabine was accompanied by reduced 
sensitivity to afatinib and erlotinib and vice versa, indicating 
the acquisition of a drug cross-resistance phenotype (Table II). 
However, the changes in sensitivity to other chemotherapeutic 
agents did not follow the same pattern in the cell lines. For 
example, while BxPc3GEMR and BxPc3AFR cells showed an 
increase in sensitivity to oxaliplatin treatment, the IC50 value 
in BxPc3OSIR for oxaliplatin was increased by almost 3-fold 
(p<0.05). Similarly, while there was no significant change in 
the sensitivity of BxPc3AFR cells to treatment with doxycy-
cline, both BxPc3GEMR and BxPc3OSIR cells were found to 
have a significantly lower IC50 for doxycycline compared to the 
parental cell line indicating that different mechanisms could be 
contributing to the acquisition of drug resistance in these cell 
lines (Table III).
Numerous studies have identified cells with stem cell 
characteristics, that represent a small subpopulation within 
haematological or solid tumours known as cancer stem cells 
(CSCs) which have the capacity of self-renewal, differentia-
tion, and high tumourigenicity (23). According to the CSC 
model, current therapeutic strategies can eliminate the 
majority of tumour cells. However, due to their high intrinsic 
drug resistance, CSCs can escape conventional treatments 
and lead to tumour recurrence. The innate resistance of CSCs 
to treatment with conventional therapies stems from specific 
traits which confer high resistance to therapeutic agents, 
such as high detoxification capacity, increased DNA repair 
capability, increased drug efflux due to high expression of 
ABC transporters and infrequent replication (24,25). One of 
the most well established mechanisms involved in acquisi-
tion of multi-drug resistance (MDR) is the over-expression 
of drug efflux proteins, mainly the ATP-binding cassette 
(ABC) transporters. The ABC superfamily consists of 48 
members which can use energy to facilitate the transport 
Table Iv. IC50 values for STAT3 inhibitor stattic and combination index (CI) values of afatinib plus stattic or afatinib plus 
crizotinib in the parental BxPc3 cell line and its drug-resistant variants (three independent experiments). 
Cell line Stattic IC50 range Afatinib + Stattic CI range (effect) Afatinib + Crizotinib CI range (effect)
BxPc3 1.36-1.9 µM 0.503-0.603 (Synergism) 0.15-0.22 (Strong synergism)
BxPc3AFR 703-774 nMa 0.86-0.98 (Additive) 0.73-0.87 (Slight synergism)
BxPc3GEMR 691-775 nMa 1.05-1.08 (Additive) 0.96-1.07 (Additive)
BxPc3OSIR 1.22-1.27 µM 0.72-0.85 (Additive/Slight synergism) 0.7-0.88 (Additive/Slight synergism)
Interpretation of the results was based on the proposed descriptions for presenting the degrees of antagonism or synergism by Calcusyn 
software. (ap<0.05).
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of various agents and therefore, can confer a multidrug 
phenotype (26,27).
Therefore, we started to examine the expression levels 
of several CSC markers including CD133, CD24 and CD44 
as well as some of the basic members of ABC transporters 
such as P-glycoprotein (P-gp) in the developed drug-resistant 
variants (28-30). Noteworthy, of all markers investigated, 
CD44 expression was found to be increased in BxPc3AFR 
and BxPc3OSIR drug-resistant variants (Table Iv). However, 
the percentage of the population of CD44 positive cells in 
these drug-resistant variants was above 99%, indicating 
that the upregulation of CD44 was not restricted to a small 
subpopulation of these cells. Since CD44 can associate 
directly with HER family members and enhance their activa-
tion and subsequent mitogenic signals, we hypothesized that 
CD44 overexpression could be involved in the acquisition 
of resistance in these cell lines (31-33). However, addition 
of a blocking anti-CD44 antibody to treatment of these cell 
lines with HER inhibitors erlotinib and afatinib, failed to 
re-sensitize them to the latter (data not shown). In addition, 
with the exception of a small increase (not significant) in 
ABCG2 expression in BxPc3AFR cells, there were no major 
changes in the expression of ABC transporters investigated 
(P-gp, MRP-2 and ABCG2) in all drug-resistant variants 
(data not shown).
The phosphorylation status of various tyrosine residues 
of EGFR exhibited several differences between the parental 
cell line and the drug-resistant variants. For example, even 
though phosphorylation levels of Y1148 and Y1045 were 
similar between the parental cell line and its drug-resistant 
variants, an increase of phosphorylation of Y1068 and Y1173 
was observed in the BxPc3AFR and BxPc3GEMR clones 
(Fig. 4). Furthermore, afatinib at 400 nM, led to an almost 
complete inhibition of EGFR phosphorylation at tyrosine 
1068 only in the parental BxPc3 cells (Fig. 5). In addition, we 
found a 3-fold increase in the autocrine production of amphi-
regulin in the BxPc3AFR and BxPc3GMER variants but not 
BxPc3OSIR compared to the parental cell line, indicating 
that the differences in the phosphorylation of EGFR tyrosine 
residues or the low efficacy of afatinib could result from the 
presence of an amphiregulin autocrine loop. However, addi-
tion of an anti-EGFR antibody (ICR62 at 200 nM) to afatinib 
treatment failed to re-sensitize them to the latter, indicating 
that AR over expression alone could not explain the acquisi-
tion of resistance to anti-HER treatment in these cell lines 
(data not shown).
Next generation sequencing using the CHPv2 pool 
of primers, revealed no differences between the parental 
cell line and its drug-resistant variants in 2855 hot spots/
COSMIC mutations from 50 genes including EGFR, 
HER2, KRAS, p53, PIK3CA, PTEN and c-MET among 
others. However, the possibility of mutations in these 
genes leading to drug resistance cannot be excluded and 
could be addressed only by full gene-sequencing for these 
biomarkers (Table III).
Several studies have shown that c-MET signalling can 
be involved in the acquisition of drug resistance to either 
HER inhibitors or gemcitabine through overexpression of 
the receptor or hyperactivation of the c-MET/HGF signal-
ling axis (34-38). Of note, despite increased phosphorylation 
of c-MET in all drug-resistant variants, growth inhibition 
analysis showed no significant change in the sensitivity to the 
c-MET inhibitor crizotinib. In addition, while treatment with 
crizotinib (400 nM) blocked the phosphorylation of c-MET 
completely, it had no effect on the phosphorylation status of 
STAT3, MAPK or AKT (Table I and Fig. 5).
Activation of STAT3 has also been implicated in resis-
tance to HER inhibitors or cytotoxics in several malignancies 
such as lung cancer, non-Hodgkin's lymphoma and multiple 
myeloma (39-42). In non-small cell lung cancer cells, 
Kim et al found that resistance to afatinib is mediated by the 
activation of STAT3 via the IL-6R/JAK1 signalling axis (43). 
More recently, STAT3 has been found to have a critical role 
in conferring resistance to anoikis and promote metastasis 
in pancreatic cancer cells (44). STAT3 has been shown to 
be activated in an EGFR-dependent mechanism through 
association of STAT3 with the EGFR tyrosine residues 
1068 and 1086 which act as docking sites, as well as EGFR-
independent mechanisms, including the IL-6 receptor, SRC 
family kinases and JAK (45). In our study, while short term 
treatment with AR led to a significant increase of phosphory-
lation in all EGFR tyrosine residues tested in the parental cell 
line, it had no effect on STAT3 phosphorylation (Fig. 2B). In 
addition, as mentioned above, even though afatinib inhibited 
the phosphorylation of EGFR at Y1068 in all drug-resistant 
variants, it had no effect on the activation status of STAT3, 
indicating that upregulation of p-STAT3 was a result of an 
EGFR independent mechanism and warrants further inves-
tigation (Fig. 5).
Of note, we found that treatment with the STAT3 inhibitor 
Stattic, had a higher inhibitory effect on the drug-resistant 
variants compared with the parental cell line (Table Iv). 
Other studies have also indicated that inhibition of STAT3 in 
some cancer types can re-sensitize cells that have acquired 
resistance to EGFR inhibitors or chemotherapeutics (40,46). 
Currently, the therapeutic potential of STAT3 inhibition is 
being pursued in two separate lung cancer studies: i) A phase 
I/II trial of Ruxolitinib (a JAK1/2 inhibitor) in combination 
with erlotinib in patients with lung adenocarcinoma (EGFR-
mutant), with acquired resistance to erlotinib (ClinicalTrials.
gov identifier: NCT02155465) and ii) a phase I trial of 
afatinib plus ruxolitinib in non-small lung cancer (NSCLC) 
patients (ClinicalTrials.gov identifier: NCT02145637) will 
provide more information on this new therapeutic concept. In 
our preclinical study, when Stattic was used in combination 
with afatinib, it led to an additive effect in all drug-resistant 
pancreatic cancer variants (Table Iv). In contrast, the combi-
nation of Stattic with gemcitabine led to an antagonistic 
effect (data not shown). In addition, while the sensitivity 
of the drug-resistant variants to treatment with the c-MET 
inhibitor crizotinib remained unchanged, a combination of 
afatinib with the latter produced an additive or synergistic 
effect indicating the therapeutic potential of this combina-
tion in overcoming resistance of pancreatic cancer cells to 
HER inhibitors and warrants further investigation.
In conclusion, our results indicate that the activation of 
STAT3 may play an important role in the acquisition of resis-
tance to gemcitabine and HER inhibitors in pancreatic cancer 
and warrant further investigations on the therapeutic potential 
of STAT3 inhibitors in such a setting.
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